Methods and compositions for oral administration of proteins
AssigneeOramed Ltd.
InventorMiriam Kidron
Life of this patent
Estimating the term…
Abstract
This invention provides compositions that include a protein and at least two protease inhibitors, method for treating diabetes mellitus, and methods for administering same, and methods for oral administration of a protein with an enzymatic activity, including orally administering same.
Claims29
A method for increasing the bioavailability of a protein to a subject, the method comprising:
- orally administering, to the subject, a pharmaceutical composition that comprises the protein,
- wherein the subject is in need of the protein,
- wherein the pharmaceutical composition further comprises two protease inhibitors and a pharmaceutically acceptable carrier in a pharmaceutically acceptable formulation,
- wherein the protein is insulin, Exenatide, somatotropin, insulin growth factor-I, an oxidoreductase, a transferase, a hydrolase, a lyase, an isomerase, a ligase, an annexin, an ATP-binding cassette transporter, hemoglobin, an ATPase, a calcium channel, a potassium channel, a sodium channel, a solute carrier, an albumin, lactoglobulin, casein, ovomucin, ferritin, phosvitin, lactoferrin, vitellogenin, amyloid, collagen, elastin, fibrillin or glucagon, and
- wherein the protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin,
- whereby the protease inhibitors increase the bioavailability of the protein when the composition is administered orally to the subject.
A method for treating diabetes mellitus in a subject, comprising:
- orally administering a pharmaceutical composition that comprises insulin or Exenatide, or both insulin and Exenatide, thereby treating the diabetes mellitus, wherein the pharmaceutical composition further comprises
- two protease inhibitors and a pharmaceutically acceptable carrier in a pharmaceutically acceptable formulation, and
- wherein the protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin,
- whereby the protease inhibitors increase the bioavailability of the insulin and Exenatide when the composition is administered orally to the subject.
A method for administration of insulin to a human subject in need of insulin, the method comprising:
- orally administering a pharmaceutical composition that comprises insulin to the human subject, the pharmaceutical composition further comprising
- two protease inhibitors and a pharmaceutically acceptable carrier in a pharmaceutically acceptable formulation, and
- wherein the protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin,
- whereby the protease inhibitors increase the bioavailability of the insulin when the composition is administered orally to the human subject.
A method for administration of Exenatide to a human subject in need of Exenatide, the method comprising:
- orally administering a pharmaceutical composition that comprises Exenatide to the human subject, the pharmaceutical composition further comprising
- two protease inhibitors and a pharmaceutically acceptable carrier in a pharmaceutically acceptable formulation, and
- wherein the protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin,
- whereby the protease inhibitors increase the bioavailability of the Exenatide when the composition is administered orally to the human subject.
A method for administration of glucagon to a human subject in need of glucagon, the method comprising:
- orally administering a pharmaceutical composition that comprises glucagon to the human subject, the pharmaceutical composition further comprising
- two protease inhibitors and a pharmaceutically acceptable carrier in a pharmaceutically acceptable formulation, and
- wherein the protease inhibitors consist of Soybean Trypsin Inhibitor (SBTI) and aprotinin,
- whereby the protease inhibitors increase the bioavailability of the glucagon when the composition is administered orally to the human subject.
Dependencies are inferred from the claim text.